Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of Qingda Granules for grade 1 essential hypertension with liver-yang hyperactivity syndrome
CTR20244433Phase 2Active
- Sponsor
- Fujian University of Traditional Chinese Medicine
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Qingda Granules in essential hypertension, sponsored by Fujian University of Traditional Chinese Medicine. Started Oct 2025; status: active.
02
Drugs
Qingda Granules
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20244433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244433.